On 2016 Jul 15, Anthony Jorm commented:

In their response to the letter by Jorm et al which questioned whether scaling up of treatment is likely to reduce prevalence of depression and anxiety Jorm AF, 2016, Chisholm and colleagues commented that “population ageing… in many contexts will cancel out or more than counteract the impact of treatment” Chisholm D, 2016. As far as high income countries are concerned, this is unlikely. A review of age group differences in the risk of anxiety and depression found that the evidence supported a reduction of risk with older age Jorm AF, 2000. These findings imply that population ageing is unlikely to counteract the impact of increased provision of treatment on the prevalence of depression and anxiety in high-income countries.

On 2016 Jul 15, Anthony Jorm commented:

In their response to the letter by Jorm et al which questioned whether scaling up of treatment is likely to reduce prevalence of depression and anxiety Jorm AF, 2016, Chisholm and colleagues commented that “population ageing… in many contexts will cancel out or more than counteract the impact of treatment” Chisholm D, 2016. As far as high income countries are concerned, this is unlikely. A review of age group differences in the risk of anxiety and depression found that the evidence supported a reduction of risk with older age Jorm AF, 2000. These findings imply that population ageing is unlikely to counteract the impact of increased provision of treatment on the prevalence of depression and anxiety in high-income countries.